LUPRON DEPOT-PED KIT (Leuprolide Acetate) Patent Expiration, LOE Window & CMS Spending

LUPRON DEPOT-PED KIT (Leuprolide Acetate) by AbbVie: FDA Orange Book core substance LOE 2031-02-05, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN020263 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-05
Last Listed Patent or Exclusivity Date2031-02-05
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 17.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.